Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (11003)
  2. Meeting Abstract (9530)
  3. Review (575)
  4. Book Section (417)
  5. Editorial (341)
  6. Guidelines (161)
  7. Correspondence (120)
  8. Conference Paper (107)
  9. Research Letter (63)
  10. Miscellaneous (55)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22375)
  2. GSK Faculty (5952)
  3. Genitourinary Oncology Service (5683)
  4. Survivorship Research (5261)
  5. Gastrointestinal Oncology Service (4738)
  6. Breast Medicine Service (4179)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. Clifford Hudis (906)
  4. Jedd Wolchok (905)
  5. Mark Kris (873)
  6. Eileen O'Reilly (800)

More People

Years
  1. 2025 (775)
  2. 2024 (1389)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5297)
  2. Annals of Oncology (1309)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (781)
  5. Journal of Thoracic Oncology (534)
  6. Gynecologic Oncology (443)

More Publications

Publishers
  1. American Society of Clinical Oncology (5592)
  2. American Association for Cancer Research (2332)
  3. Elsevier Inc. (2239)
  4. Oxford University Press (1838)
  5. Nature Publishing Group (1052)
  6. Springer (992)

More Publishers

Results (22399)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A first-in-human phase 1 study Of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors (trial in progress)
    Meeting Abstract

    Ray-Coquard, I. L.; O'Malley, D. M.; Oaknin, A.; Pothuri, B.; Lorusso, D.; Eskander, R. N.; Westin, S. N.; Lakhani, N.; McKean, W. B.; Koyama, T.; more...
    International Journal of Gynecological Cancer (2025)

    Fulltext@MSK | Save
  • An open-label, multicentre, phase 2 study of trastuzumab deruxtecan in patients with HER2-expressing solid tumours: DESTINY-PanTumor02 Part 2
    Meeting Abstract

    Oaknin, A.; Lee, J. Y.; Makker, V.; Oh, D. Y.; Anoka, C.; Jung, L.; Puvvada, S.; Simões, J.; Meric-Bernstam, F.
    International Journal of Gynecological Cancer (2025)

    Fulltext@MSK | Save
  • Multimodal AI modeling of clinical panel-based sequencing for HRD detection in ovarian cancer
    Meeting Abstract

    Alsaafin, A.; Pollard, T.; Aukerman, A. T.; Boehm, K.; Pasha, A.; Moore, D.; Rusk, N.; Begum, A.; Sullivan, M. W.; Graves, S.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Impact of tumor burden at progression and changes in risk scores from baseline in patients with advanced renal cell carcinoma treated with lenvatinib + pembrolizumab: Phase 3 CLEAR trial
    Meeting Abstract

    Grünwald, V.; Keizman, D.; Bedke, J.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; Merchan, J. R.; Eto, M.; more...
    Asia-Pacific Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • IDH2-mutated cholangiocarcinoma: A case series highlighting challenges and insights
    Meeting Abstract

    Al Mahmasani, L.; Harding, J. J.; Thummalapalli, R.; Khalil, D.; Yaqubie, A.; O'Reilly, E. M.; Abou-Alfa, G. K.
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases
    Meeting Abstract

    Schlechter, B. L.; Fakih, M.; Tsimberidou, A. M.; Bullock, A.; Pimentel, A.; Sharma, S.; Lenz, H. J.; Gordon, M.; Abou-Alfa, G. K.; Marron, T.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • BREAKWATER: Post-hoc subgroup efficacy analyses by chemotherapy ± bevacizumab regimens vs encorafenib plus cetuximab + mFOLFOX6
    Meeting Abstract

    Yoshino, T.; Kopetz, S.; Van Cutsem, E.; Wasan, H. S.; Eng, C.; Yaeger, R.; Kim, T. W.; Ciardiello, F.; Maughan, T.; Desai, J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma
    Meeting Abstract

    Al-Batran, S. E.; Wainberg, Z. A.; Muro, K.; Molena, D.; Van Cutsem, E.; Hyung, W. J.; Wyrwicz, L. S.; Moehler, M.; Herrero, F. R.; Oh, D. Y.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers
    Meeting Abstract

    Fernandez, E. E.; Garralda, E.; Parikh, A.; Italiano, A.; Hollebecque, A.; Marabelle, A.; Friedman, C.; Sullivan, R.; Tschernia, N.; Juarez, M. M. H.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial
    Meeting Abstract

    Macarulla Mercade, T.; Bekaii-Saab, T.; Feeney, K.; O'Reily, E. M.; Pant, S.; Park, J. O.; Prager, G.; Seufferlein, T.; Boakye, M.; He, X.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save